MX2019010732A - Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. - Google Patents
Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.Info
- Publication number
- MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A
- Authority
- MX
- Mexico
- Prior art keywords
- catecholamine
- cst
- syndrome
- bind
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469296P | 2017-03-09 | 2017-03-09 | |
| PCT/US2018/021592 WO2018165460A1 (en) | 2017-03-09 | 2018-03-08 | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010732A true MX2019010732A (es) | 2019-11-01 |
Family
ID=63446773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010732A MX2019010732A (es) | 2017-03-09 | 2018-03-08 | Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11045482B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3592358A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7564620B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110475558A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018230429B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3053806A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019010732A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018165460A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007402A (es) | 2018-12-20 | 2021-07-15 | Corcept Therapeutics Inc | Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina. |
| JP2021079146A (ja) * | 2021-02-22 | 2021-05-27 | 株式会社三洋物産 | 遊技機 |
| JP7315071B2 (ja) * | 2021-03-03 | 2023-07-26 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
| CA2246791A1 (en) | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
| US6818739B2 (en) | 1999-12-03 | 2004-11-16 | Ndsu Research Foundation | Somatostatins |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| JP2004525135A (ja) | 2001-03-23 | 2004-08-19 | コーセプト セラピューティクス, インコーポレイテッド | 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法 |
| WO2003057214A1 (en) | 2001-12-28 | 2003-07-17 | Somatocor Pharmaceuticals, Inc. | Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands |
| RU28362U1 (ru) | 2002-12-10 | 2003-03-20 | Закрытое акционерное общество "Дальневосточная технология" | Лист заходной футеровки |
| JP4931794B2 (ja) | 2004-03-09 | 2012-05-16 | コーセプト セラピューティクス, インコーポレイテッド | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| EP2145186A4 (en) * | 2007-05-15 | 2010-10-20 | Water Technologies Corp | DEVICE AND METHOD FOR THE DETECTION OF METANEPHRINES IN PLASMA |
| EP2532350A1 (en) | 2007-10-17 | 2012-12-12 | Laboratoire HRA Pharma | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome |
| ES2351569B8 (es) | 2009-05-07 | 2012-06-20 | Bcn Peptides S.A. | Ligandos peptídicos de receptores de somatostatina. |
| AU2010247766B2 (en) | 2009-05-12 | 2015-05-21 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| WO2011094814A1 (en) * | 2010-02-05 | 2011-08-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| CN103596431B (zh) | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| WO2013039916A1 (en) * | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| ES2943542T3 (es) | 2013-11-25 | 2023-06-14 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| JP6821582B2 (ja) * | 2015-03-02 | 2021-01-27 | コーセプト セラピューティクス, インコーポレイテッド | Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用 |
| US9943526B2 (en) * | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
-
2018
- 2018-03-08 CA CA3053806A patent/CA3053806A1/en active Pending
- 2018-03-08 CN CN201880015928.3A patent/CN110475558A/zh active Pending
- 2018-03-08 WO PCT/US2018/021592 patent/WO2018165460A1/en not_active Ceased
- 2018-03-08 US US15/915,284 patent/US11045482B2/en active Active
- 2018-03-08 AU AU2018230429A patent/AU2018230429B2/en active Active
- 2018-03-08 EP EP18763240.1A patent/EP3592358A4/en active Pending
- 2018-03-08 MX MX2019010732A patent/MX2019010732A/es unknown
- 2018-03-08 JP JP2019548370A patent/JP7564620B2/ja active Active
-
2022
- 2022-04-21 JP JP2022070027A patent/JP2022090003A/ja not_active Withdrawn
-
2024
- 2024-03-28 JP JP2024053332A patent/JP2024074854A/ja not_active Withdrawn
-
2026
- 2026-04-03 JP JP2026061808A patent/JP2026099911A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110475558A (zh) | 2019-11-19 |
| US20180256604A1 (en) | 2018-09-13 |
| CA3053806A1 (en) | 2018-09-13 |
| JP7564620B2 (ja) | 2024-10-09 |
| JP2024074854A (ja) | 2024-05-31 |
| WO2018165460A1 (en) | 2018-09-13 |
| EP3592358A1 (en) | 2020-01-15 |
| JP2020510011A (ja) | 2020-04-02 |
| EP3592358A4 (en) | 2020-12-16 |
| US11045482B2 (en) | 2021-06-29 |
| AU2018230429B2 (en) | 2023-06-15 |
| JP2022090003A (ja) | 2022-06-16 |
| JP2026099911A (ja) | 2026-06-18 |
| AU2018230429A1 (en) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
| ZA202006481B (en) | Anti-msr1 antibodies and methods of use thereof | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MY199903A (en) | Combination therapy with controlled-release cnp agonists | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| GB2454118A (en) | Hdac inhibitors and hormone targeted drugs for the treatment of cancer | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| PL2288413T3 (pl) | Urządzenie terapeutyczne łączące radioterapię z termoterapią | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| JOP20200124A1 (ar) | طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| MX2021007402A (es) | Metodos para la toma de imagenes y el tratamiento de tumores positivos para el receptor de somatostatina. |